Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

This clinical trial is designed to understand the safety and effectiveness of human amniotic membrane mesenchymal stem cells (hA-MSCs) in the treatment of primary ovarian insufficiency (POI). Human amniotic MSCs were infused back into the patients by intravenous injection. The trial was designed with two groups, 1) the control group by conventional hormone replacement therapy with oral Climen and 2) the stem cell treatment group by intravenous infusion of human amniotic membrane mesenchymal stem cells (hA-MSCs) combined with oral Climen hormone therapy. Patients were followed up every 2 weeks after the post-injection stem cells to observe their outcomes. The investigators focused on safety indicators, but also monitored hormone levels and signs of follicular growth to initially assess the effectiveness of the stem cells.

Inclusion criteria

• The intention of pregnant women aged >= 20 and < 40, with normal karyotype;
• Oligo/amenorrhea for at least 4 months;
• Elevated FSH level >25 IU/l on two occasions >4 weeks apart;
• Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months;
• Voluntary participation in the study with signed informed consent;

Exclusion criteria

• Unable to follow the treatment observation process required by the trial;
• Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure;
• With breast, uterine, ovarian tumors, or any other benign or malignant tumors;
• Allergic history to drugs or any other things;
• Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs.
• Have undergone ovariectomy or have organic gynaecological diseases.
• Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome.
• Severe functional impairment of vital organs.
• High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms.
• Attending doctor considers inappropriate to take part in.